Identifying patients at high risk for nausea and vomiting after chemotherapy: The development of a practical prediction tool: I. Acute nausea and vomiting

Journal of Supportive Oncology

Volumn 7, Issue 4, 2009, Pages

  Dranitsaris, George ^a,b,c   Joy, Anil ^a,b,c   Young, Scott ^a,b,c   Clemons, Mark ^a,b,c   Callaghan, Walter ^a,b,c   Petrella, Teresa ^a,b,c  

^a DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

^b CROSS CANCER INSTITUTE   (Canada)

^c Northeastern Ontario Regional Cancer Centre   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTIEMETIC AGENT; DEXAMETHASONE; GRANISETRON; ONDANSETRON; PLATINUM COMPLEX;

ADULT; AGE DISTRIBUTION; AGED; ALCOHOL CONSUMPTION; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER LOCALIZATION; CANCER STAGING; CHEMOTHERAPY INDUCED EMESIS; CONTROLLED STUDY; DIGESTIVE SYSTEM CANCER; FEMALE; GYNECOLOGIC CANCER; HIGH RISK PATIENT; HUMAN; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; NAUSEA AND VOMITING; OUTCOME ASSESSMENT; PATIENT IDENTIFICATION; PRACTICE GUIDELINE; PRESCRIPTION; SENSITIVITY AND SPECIFICITY; UROGENITAL TRACT CANCER;

EID: 70349242064     PISSN: 15446794     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. de Boer-Dennert M, de Wit R, Schmitz PI, et al. Patient perceptions of the side-effects of chemotherapy: the influence of 5HT3 antagonists. Br J Cancer 1997;76:1055-1061.
2. Sun CC, Bodurka DC, Weaver CB, et al. Rankings and symptom assessments of side effects from chemotherapy: insights from experienced patients with ovarian cancer. Support Care Cancer 2005;13:219-227.
3. Lee J, Dibble SL, Pickett M, Luce J. Chemotherapy-induced nausea/ vomiting and functional status in women treated for breast cancer. Cancer Nurs 2005;28:249-255.
4. Rusthoven JJ, Osoba D, Butts CA, Yelle L, Findlay H, Grenville A. The impact of postchemotherapy nausea and vomiting on quality of life after moderately emetogenic chemotherapy. Support Care Cancer 1998;6:389-395.
5. Osoba D, Zee B, Warr D, Latreille J, Kaizer L, Pater J. Effect of postchemotherapy nausea and vomiting on health-related quality of life. Quality of Life and Symptom Committees of the National Cancer Institute of Canada Clinical Trials Group. Support Care Cancer 1997;5:307-313.
6. Martin M. The severity and pattern of emesis following different cytotoxic agents. Oncology 1996;53(suppl 1):26-31.
7. Verweij J, de Wit R, de Mulder PH. Optimal control of acute cisplatin-induced emesis. Oncology 1996;53(suppl 1):56-64.
8. Ossi M, Anderson E, Freeman A. 5-HT3 receptor antagonists in the control of cisplatin-induced delayed emesis. Oncology 1996;53(suppl 1):78-85.
9. Patel L, Lindley C. Aprepitant - a novel NK1-receptor antagonist. Expert Opin Pharmacother 2003;4:2279-2296.
10. Morrow GR, Roscoe JA, Hickok JT, et al. Initial control of chemotherapy-induced nausea and vomiting in patient quality of life. Oncology (Williston Park) 1998;12(3 suppl 4):32-37.
11. Watson M, Meyer L, Thomson A, Osofsky S. Psychological factors predicting nausea and vomiting in breast cancer patients on chemotherapy. Eur J Cancer 1998;34:831-837.
12. Tsavaris N, Kosmas C, Mylonakis N, et al. Parameters that influence the outcome of nausea and emesis in cisplatin based chemotherapy. Anticancer Res 2000;20:4777-4783.
13. Osoba D, Zee B, Pater J, Warr D, Latreille J, Kaizer L. Determinants of postchemotherapy nausea and vomiting in patients with cancer. Quality of Life and Symptom Committees of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1997;15:116-123.
14. Molassiotis A, Yam BM, Yung H, Chan FY, Mok TS. Pretreatment factors predicting the development of postchemotherapy nausea and vomiting in Chinese breast cancer patients. Support Care Cancer 2002;10:139-145.
15. George SL. Identification and assessment of prognostic factors. Semin Oncol 1988;15:462-471.
16. Klastersky J, Paesmans M, Rubenstein EB, et al. The Multinational Association for Supportive Care in Cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol 2000;18:3038-3051.
17. Allison PD. Logistic Regression Using the SAS System: Theory and Application. Cary, NC: SAS Institute Inc; 1999:179-216.
18. Steyerberg EW, Eijkemans MJ, Harrell FE Jr, Habbema JD. Prognostic modeling with logistic regression analysis: in search of a sensible strategy in small data sets. Med Decis Making 2001;21:45-56.
19. Steyerberg EW, Harrell FE Jr, Borsboom GJ, Eijkemans MJ, Vergouwe Y, Habbema JD. Internal validation of predictive models: efficiency of some procedures for logistic regression analysis. J Clin Epidemiol 2001;54:774-781.
20. American Society of Clinical Oncology, Kris MG, Hesketh PJ, Somerfield MR, et al. American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006. J Clin Oncol 2006;24:2932-2947.
21. Hesketh PJ. Defining the emetogenicity of cancer chemotherapy regimens: relevance to clinical practice. Oncologist 1999;4:191-196.
22. McNeil BJ, Hanley JA. Statistical approaches to the analysis of receiver operating characteristic (ROC) curves. Med Decis Making 1984;4:137-150.
23. Zweig MH, Campbell G. Receiver-operating characteristic plots: a fundamental evaluation tool in clinical medicine. Clin Chem 1993;39:561-577.
24. du Bois A, Meerpohl HG, Vach W, Kommoss FG, Fenzl E, Pfleiderer A. Course, patterns, and risk-factors for chemotherapy-induced emesis in cisplatin-pretreated patients: a study with ondansetron. Eur J Cancer 1992;28:450-457.
25. Dibble SL, Casey K, Nussey B, Israel J, Luce J. Chemotherapy-induced vomiting in women treated for breast cancer. Oncol Nurs Forum 2004;31:E1-E8.
26. Dranitsaris G, Clemons M, Verma S, Lau C, Vincent M. Chemotherapy-induced anaemia during adjuvant treatment for breast cancer: development of a prediction model. Lancet Oncol 2005;6:856-863.
27. Dranitsaris G, Shah A, Spirovski B, Vincent M. Severe diarrhea in patients with advanced-stage colorectal cancer receiving FOLFOX or FOLFIRI chemotherapy: the development of a risk prediction tool. Clin Colorectal Cancer 2007;6:367-373.